Efficacy and safety comparison of PD-1 inhibitors vs. PD-L1 inhibitors in extensive-stage small-cell lung cancer: a retrospective comparative cohort study

BACKGROUND: Evidence from clinical research and meta-analyses have suggested that programmed cell death 1 (PD-1) inhibitors and programmed cell death ligand 1 (PD-L1) inhibitors plus chemotherapy could achieve a significant survival benefit for extensive-stage small-cell lung cancer (ES-SCLC) patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Guanghui, Sun, Hongfu, Sun, Nini, Huang, Wei, Wang, Zhongtang, Zhang, Huawei, Liu, Chengxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840043/
https://www.ncbi.nlm.nih.gov/pubmed/36647464
http://dx.doi.org/10.21037/jtd-22-1682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840043/
https://www.ncbi.nlm.nih.gov/pubmed/36647464
http://dx.doi.org/10.21037/jtd-22-1682

Ejemplares similares